Literature DB >> 28986474

Digging Deeper into CYP3A Testosterone Metabolism: Kinetic, Regioselectivity, and Stereoselectivity Differences between CYP3A4/5 and CYP3A7.

Sylvie E Kandel1, Lyrialle W Han1, Qingcheng Mao1, Jed N Lampe2.   

Abstract

The metabolism of testosterone to 6β-hydroxytestosterone (6β-OH-T) is a commonly used assay to evaluate human CYP3A enzyme activities. However, previous reports have indicated that CYP3A7 also produces 2α-hydroxytestosterone (2α-OH-T) and that a 2α-OH-T/6β-OH-T ratio may be a unique endogenous biomarker of the activity of the enzyme. Until now, the full metabolite and kinetic profile for testosterone hydroxylation by CYP3A7 has not been fully examined. To this end, we performed a complete kinetic analysis of the 6β-OH-T, 2α-OH-T, and 2β-hydroxytestosterone metabolites for recombinant Supersome CYP3A4, CYP3A5, and CYP3A7 enzymes and monitored metabolism in fetal and adult human liver microsomes for comparison. In general, a decrease in the velocity of the reaction was observed between CYP3A4 and the two other enzymes, with CYP3A7 showing the lowest metabolic capacity. Interestingly, we found that the 2α-OH-T/6β-OH-T ratio varied with substrate concentration when testosterone was incubated with CYP3A7, suggesting that this ratio would likely not function well as a biomarker for CYP3A7 activity. In silico docking studies revealed at least two different binding modes for testosterone between CYP3A4 and CYP3A7. In CYP3A4, the most energetically favorable docking mode places testosterone in a position with the methyl groups directed toward the heme iron, which is more favorable for oxidation at C6β, whereas for CYP3A7 the testosterone methyl groups are positioned away from the heme, which is more favorable for an oxidation event at C2α In conclusion, our data indicate an alternative binding mode for testosterone in CYP3A7 that favors the 2α-hydroxylation, suggesting significant structural differences in its active site compared with CYP3A4/5.
Copyright © 2017 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28986474      PMCID: PMC5697443          DOI: 10.1124/dmd.117.078055

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  70 in total

1.  Alanine-scanning mutagenesis of a putative substrate recognition site in human cytochrome P450 3A4. Role of residues 210 and 211 in flavonoid activation and substrate specificity.

Authors:  G R Harlow; J R Halpert
Journal:  J Biol Chem       Date:  1997-02-28       Impact factor: 5.157

2.  Identification of CYP3A7 for glyburide metabolism in human fetal livers.

Authors:  Diana L Shuster; Linda J Risler; Bhagwat Prasad; Justina C Calamia; Jenna L Voellinger; Edward J Kelly; Jashvant D Unadkat; Mary F Hebert; Danny D Shen; Kenneth E Thummel; Qingcheng Mao
Journal:  Biochem Pharmacol       Date:  2014-10-22       Impact factor: 5.858

3.  Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism.

Authors:  K E Kenworthy; S E Clarke; J Andrews; J B Houston
Journal:  Drug Metab Dispos       Date:  2001-12       Impact factor: 3.922

4.  Chromatographic assays of drug oxidation by human cytochrome P450 3A4.

Authors:  Christal D Sohl; Qian Cheng; F Peter Guengerich
Journal:  Nat Protoc       Date:  2009-08-06       Impact factor: 13.491

5.  Amino acid 305 determines catalytic center accessibility in CYP3A4.

Authors:  S M Fowler; R J Riley; M P Pritchard; M J Sutcliffe; T Friedberg; C R Wolf
Journal:  Biochemistry       Date:  2000-04-18       Impact factor: 3.162

6.  Roles of cytochromes P450 1A2 and 3A4 in the oxidation of estradiol and estrone in human liver microsomes.

Authors:  H Yamazaki; P M Shaw; F P Guengerich; T Shimada
Journal:  Chem Res Toxicol       Date:  1998-06       Impact factor: 3.739

7.  Metabolism of 4 beta -hydroxycholesterol in humans.

Authors:  Karl Bodin; Ulla Andersson; Eva Rystedt; Ewa Ellis; Maria Norlin; Irina Pikuleva; Gösta Eggertsen; Ingemar Björkhem; Ulf Diczfalusy
Journal:  J Biol Chem       Date:  2002-06-20       Impact factor: 5.157

8.  Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups.

Authors:  Su-Jun Lee; Khawja A Usmani; Brian Chanas; Burhan Ghanayem; Tina Xi; Ernest Hodgson; Harvey W Mohrenweiser; Joyce A Goldstein
Journal:  Pharmacogenetics       Date:  2003-08

9.  The human intestinal cytochrome P450 "pie".

Authors:  Mary F Paine; Heather L Hart; Shana S Ludington; Robert L Haining; Allan E Rettie; Darryl C Zeldin
Journal:  Drug Metab Dispos       Date:  2006-02-07       Impact factor: 3.922

10.  Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6 beta-hydroxylase cytochrome P-450 enzyme.

Authors:  D J Waxman; C Attisano; F P Guengerich; D P Lapenson
Journal:  Arch Biochem Biophys       Date:  1988-06       Impact factor: 4.013

View more
  9 in total

Review 1.  Neonatal cytochrome P450 CYP3A7: A comprehensive review of its role in development, disease, and xenobiotic metabolism.

Authors:  Haixing Li; Jed N Lampe
Journal:  Arch Biochem Biophys       Date:  2019-08-22       Impact factor: 4.013

2.  Stereoselective Oxidation Kinetics of Deoxycholate in Recombinant and Microsomal CYP3A Enzymes: Deoxycholate 19-Hydroxylation Is an In Vitro Marker of CYP3A7 Activity.

Authors:  Yu-Jie Chen; Jian Zhang; Ping-Ping Zhu; Xian-Wen Tan; Qiu-Hong Lin; Wen-Xia Wang; Shan-Shan Yin; Ling-Zhi Gao; Ming-Ming Su; Chang-Xiao Liu; Liang Xu; Wei Jia; Irina F Sevrioukova; Ke Lan
Journal:  Drug Metab Dispos       Date:  2019-03-27       Impact factor: 3.922

3.  Identification of Selective CYP3A7 and CYP3A4 Substrates and Inhibitors Using a High-Throughput Screening Platform.

Authors:  Md Kabir; Elias C Padilha; Pranav Shah; Ruili Huang; Srilatha Sakamuru; Eric Gonzalez; Lin Ye; Xin Hu; Mark J Henderson; Menghang Xia; Xin Xu
Journal:  Front Pharmacol       Date:  2022-07-01       Impact factor: 5.988

4.  Anterior pituitary, sex hormones, and keratoconus: Beyond traditional targets.

Authors:  Dimitrios Karamichos; Paulina Escandon; Brenda Vasini; Sarah E Nicholas; Lyly Van; Deanna H Dang; Rebecca L Cunningham; Kamran M Riaz
Journal:  Prog Retin Eye Res       Date:  2021-11-02       Impact factor: 19.704

5.  GWAS of three molecular traits highlights core genes and pathways alongside a highly polygenic background.

Authors:  Nasa Sinnott-Armstrong; Sahin Naqvi; Manuel Rivas; Jonathan K Pritchard
Journal:  Elife       Date:  2021-02-15       Impact factor: 8.140

6.  Human Fetal Liver Metabolism of Oxycodone Is Mediated by CYP3A7.

Authors:  Sara Shum; Nina Isoherranen
Journal:  AAPS J       Date:  2021-01-12       Impact factor: 4.009

7.  Innovative C2-symmetric testosterone and androstenedione dimers: Design, synthesis, biological evaluation on prostate cancer cell lines and binding study to recombinant CYP3A4.

Authors:  Alexis Paquin; Yassine Oufqir; Irina F Sevrioukova; Carlos Reyes-Moreno; Gervais Bérubé
Journal:  Eur J Med Chem       Date:  2021-04-24       Impact factor: 7.088

8.  Characterization of fluorescent probe substrates to develop an efficient high-throughput assay for neonatal hepatic CYP3A7 inhibition screening.

Authors:  Hannah M Work; Sylvie E Kandel; Jed N Lampe
Journal:  Sci Rep       Date:  2021-09-30       Impact factor: 4.379

9.  Structural Basis for the Diminished Ligand Binding and Catalytic Ability of Human Fetal-Specific CYP3A7.

Authors:  Irina F Sevrioukova
Journal:  Int J Mol Sci       Date:  2021-05-29       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.